Clinical Trials on Newborn Hypothermia in South Africa

Total 255 results

Insmed Incorporated

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Gordon Bernard

Terminated

STIP: Statin Trial for Influenza Patients (STIP)

Influenza | Acute Respiratory Distress Syndrome | H1N1 Influenza

United States
InfaCare Pharmaceuticals Corporation, a Mallinckrodt...

Completed

Stannsoporfin With Light Therapy for Newborn Babies With Jaundice (JASMINE_204)

Hyperbilirubinemia, Neonatal | Jaundice, Neonatal

United States
University of Washington
Medical University of South Carolina; Cystic Fibrosis Foundation

Completed

Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF (STOP-OB-13)

Cystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Lung Infection

United States
Boehringer Ingelheim

Completed

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, New Zealand, Portugal, Russian Federation, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
Parion Sciences

Completed

Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, Canada
Horizon Pharma USA, Inc.

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA) (AIR-CF3)

Cystic Fibrosis

United States, Canada, Australia, New Zealand
University of Sydney
University of Pennsylvania; University of California, San Diego; University of... and other collaborators

Completed

Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis (NeOProM)

Infant, Newborn, Diseases | Infant, Premature, Diseases | Retinopathy of Prematurity | Bronchopulmonary Dysplasia | Infant, Very Low Birth Weight

Australia
Gilead Sciences

Completed

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF1)

Cystic Fibrosis

United States, Canada, Australia, New Zealand
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
Chris Goss
Cystic Fibrosis Foundation

Recruiting

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study) (ABATE)

Nontuberculous Mycobacterium Infection

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Cystic Fibrosis

United States, Belgium, Netherlands, Australia, Germany, Ireland, United Kingdom
AbbVie
Janssen Research & Development, LLC; Forest Laboratories

Completed

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Massachusetts General Hospital

Completed

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery (ASTER)

Sepsis | Critical Illness | Respiratory Failure | Acute Respiratory Distress Syndrome

United States
Laurent Pharmaceuticals Inc.
Cystic Fibrosis Foundation

Completed

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD)

Cystic Fibrosis

United States, Australia, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Cystic Fibrosis

United Kingdom, France, Germany, Australia, Switzerland, Ireland, Belgium, Denmark, Poland
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Jaeb Center for Health Research

Recruiting

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

Cystic Fibrosis

United States
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation

Recruiting

Health Outcomes of Parents With Cystic Fibrosis-Aim 2 (HOPeCF)

Cystic Fibrosis | Parenthood Status

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Pharmaxis
ethica Clinical Research Inc.; Europe: KasaConsult bvba, Hoegaarden, Belgium; Argentina: Resolution Latin America; Buenos Aires, Argentina

Completed

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, Canada, Argentina, Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Australia, Denmark, Canada, Sweden
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants

Lung Diseases | Bronchopulmonary Dysplasia

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
Boehringer Ingelheim

Terminated

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Cystic Fibrosis

United States, Spain, Belgium, Germany, Canada, United Kingdom, Sweden, France
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Bayer
Novartis

Completed

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Germany, Canada, Australia, Sweden, Denmark, Norway, United Kingdom
Mayne Pharma International Pty Ltd

Terminated

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

Lamellar Ichthyosis

United States, Spain, Canada, Germany, France, Australia, Israel, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease

Cystic Fibrosis

United States, Australia, Canada, New Zealand
Mallinckrodt

Completed

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

Bronchopulmonary Dysplasia

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Insmed Incorporated

Completed

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Australia, New Zealand, Belgium
Forest Laboratories

Completed

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
University of Washington
Cystic Fibrosis Foundation

Completed

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

Cystic Fibrosis

United States

Clinical Trials on Newborn Hypothermia in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations